Document Detail

Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice.
Jump to Full Text
MedLine Citation:
PMID:  23334241     Owner:  NLM     Status:  MEDLINE    
AIM: To investigate whether apocynin, a NADPH oxidase inhibitor, produced cardioproteictive effects in Ang II-induced hypertensive mice, and to elucidate the underlying mechanisms.
METHODS: C57BL/6 mice were subcutaneously infused Ang II for 4 weeks to mimic cardiac remodeling and fibrosis. Concomitantly the mice were administered apocynin (100 mg·kg(-1)·d(-1)) or/and the aldosterone receptor blocker eplerenone (200 mg·kg(-1)·d(-1)) via gavage for 4 weeks. Systolic blood pressure (SBP) and heart rate were measured, and transthoracic echocardiography was performed. For in vitro study, cardiac fibroblasts were treated with Ang II (10(-7) mol/L) in the presence of apocynin (10(-5) mol/L) or/and eplerenone (10(-5) mol/L). Immunohistochemistry and Western blotting were used to quantify the expression levels of NADPH oxidase and osteopontin (OPN) proteins in the cells.
RESULTS: Both apocynin and eplerenone significantly decreased SBP, and markedly improved diastolic dysfunction in Ang II-induced hypertensive mice, accompanied with ameliorated oxidative stress and cardiac fibrosis. In the Ang II-treated cardiac fibroblasts, the expression levels of NOX4 and OPN proteins were markedly upregulated. Both Apocynin and eplerenone significantly suppressed the increased expression levels of NOX4 and OPN proteins in the Ang II-treated cells. In all the experiments, apocynin and eplerenone produced comparable effects. Co-administration of the two agents did not produce synergic effects.
CONCLUSION: Apocynin produces cardioproteictive effects comparable to those of eplerenone. The beneficial effects of apocynin on myocardial oxidative stress and cardiac fibrosis might be mediated partly through a pathway involving NADPH oxidase and OPN.
Yu-qiong Li; Xiao-bo Li; Shu-jie Guo; Shao-li Chu; Ping-jin Gao; Ding-liang Zhu; Wen-quan Niu; Nan Jia
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-21
Journal Detail:
Title:  Acta pharmacologica Sinica     Volume:  34     ISSN:  1745-7254     ISO Abbreviation:  Acta Pharmacol. Sin.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-05     Completed Date:  2013-12-27     Revised Date:  2014-10-01    
Medline Journal Info:
Nlm Unique ID:  100956087     Medline TA:  Acta Pharmacol Sin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  352-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetophenones / administration & dosage,  pharmacology,  therapeutic use*
Angiotensin II / pharmacology*
Blood Pressure / drug effects
Blotting, Western
Cardiomegaly / chemically induced,  metabolism,  pathology,  prevention & control*
Cardiotonic Agents / administration & dosage,  pharmacology,  therapeutic use*
Cell Culture Techniques
Cells, Cultured
Diastole / drug effects*,  physiology
Fibroblasts / drug effects,  metabolism,  pathology
Heart Rate / drug effects
Mice, Inbred C57BL
Myocardium / metabolism,  pathology*
Oxidative Stress / drug effects*
Reg. No./Substance:
0/Acetophenones; 0/Cardiotonic Agents; 11128-99-7/Angiotensin II; B6J7B9UDTR/acetovanillone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Acta Pharmacol Sin
Journal ID (iso-abbrev): Acta Pharmacol. Sin
ISSN: 1671-4083
ISSN: 1745-7254
Publisher: Nature Publishing Group
Article Information
Download PDF
Copyright © 2013 CPS and SIMM
Received Day: 25 Month: 07 Year: 2012
Accepted Day: 05 Month: 11 Year: 2012
Print publication date: Month: 03 Year: 2013
Electronic publication date: Day: 21 Month: 01 Year: 2013
Volume: 34 Issue: 3
First Page: 352 Last Page: 359
PubMed Id: 23334241
ID: 4002490
Publisher Item Identifier: aps2012164
DOI: 10.1038/aps.2012.164

Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice
Yu-qiong Li123#
Xiao-bo Li123#
Shu-jie Guo23
Shao-li Chu12
Ping-jin Gao12
Ding-liang Zhu23
Wen-quan Niu23*
Nan Jia12*
1Department of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
2Shanghai Institute of Hypertension, Shanghai 200025, China
3State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
#These authors contributed equally to this work.


Nearly half of all patients with chronic heart failure experience diastolic dysfunction1. Although great efforts have been devoted to deciphering the pathobiology of diastolic heart failure (DHF), its underlying mechanism and therapeutic strategies remain elusive. In this context, the angiotensin II (Ang II)-induced mouse model of hypertension has been proposed to be an ideal tool to study DHF due to its major features, which include early onset heart failure during the course of hypertension and the preservation of the ejection fraction2.

Growing evidence implicates reactive oxygen species (ROS) in the pathophysiology of heart failure and Ang II-induced cardiovascular disease3. Nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase is a key enzyme that affects ROS production4. Osteopontin (OPN), a SIBLING glycoprotein, interacts with various extracellular matrices and is involved in Ang II-induced fibrosis and heart failure5. We and others previously found that the progression of diastolic dysfunction could be effectively prevented by the aldosterone receptor blocker eplerenone, and that cardiac hypertrophy and fibrosis were significantly ameliorated through the inhibition of OPN expression2,6. We therefore sought to evaluate the effect of OPN on the progression of reactive fibrosis in the Ang II-induced hypertensive mouse heart and to further explore whether apocynin (an NADPH oxidase inhibitor), alone or in conjunction with eplerenone, could regulate OPN expression through the Ang II-aldosterone system.

To achieve this goal, a hypertensive mouse model with reactive fibrosis developed in the interstitial and perivascular regions of the myocardium and without cardiomyocyte necrosis was generated by infusing Ang II. First, we examined whether apocynin had cardioprotective effects that was comparable to those of eplerenone, eg, decreasing systolic blood pressure, improving diastolic dysfunction, and ameliorating oxidative stress and cardiac fibrosis. Then, we examined the effects of apocynin and/or eplerenone on the expression of NADPH oxidase and OPN in this model to investigate the possible mechanisms underlying their functions.

Materials and methods

All animal protocols followed the guidelines of the Shanghai Jiao Tong University Animal Care and Use Committee. Eight-week-old male C57BL/6 mice (n=35) were randomized into 5 groups: a sham group, an Ang II-infused group, an apocynin treatment group, an eplerenone treatment group, and an apocynin and eplerenone combination treatment group. Ang II-infused mice were implanted with an osmotic minipump (model 2004, Alza Corp, USA) with an administrating speed of 2 μg·kg−1·min−1 and raised for 4 weeks. Concomitantly, these mice were treated with or without apocynin and/or eplerenone. Apocynin (Sigma-Aldrich, USA) was administered at a dosage of 100 mg·kg−1·d−1 in the drinking water, and eplerenone (Pfizer, USA) was administered by gavage at a dosage of 200 mg·kg−1·d−1 continuously for 4 weeks.

Blood pressure and heart rate

The systolic blood pressure (SBP) and heart rate (HR) were measured by using a tail cuff system (BP96A, Softron, Japan). At least 5 preliminary cycles were performed, and then 10 experimental measurements were taken for each mouse.

Echocardiographic analysis

The left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVSd), and left ventricular posterior wall thickness (PW) were measured by transthoracic echocardiography using a Vevo770 instrument (VisualSonics, Toronto, Canada). The percentage of left ventricular fractional shortening (FS) was used to judge the cardiac systolic function; this value was calculated as FS (%)=(LVDd–LVSd)/LVDd*100.

The left lateral position was chosen to obtain optimal Doppler image quality. The left ventricular inflow tract was interrogated from the apical four-chamber view with the sample volume at the tips of the mitral leaflets. The E wave velocity (E/A) ratio and isovolumic relaxation time (IVRT) were measured to estimate cardiac diastolic function.

Histological analysis

The mouse hearts were fixed with 10% formalin, embedded in paraffin, sectioned at 5 μm and then stained with hematoxylin-eosin to evaluate overall morphology and Masson's trichrome to evaluate fibrosis. Myocyte breadth was measured in the hematoxylin-eosin-stained sections, and suitable cross sections were defined as having nearly circular capillary profiles and nuclei. Myocyte breadth was measured in 100 cells (per mouse) from a randomly selected section of the left ventricular lateral-mid free wall. The collagen fraction was calculated as the ratio of the sum of the total interstitial fibrosis area to the sum of the total connective tissue area plus the myocyte area in an entire visual field. The area of perivascular fibrosis was determined as the ratio of the area of fibrosis surrounding the vessel wall to the total vessel area. Approximately 10 arterial cross sections were examined for each mouse heart.

Assay of oxidative stress

Myocardial tissues were homogenized in RIPA lysis buffer. The lipid peroxide content of the left ventricular was determined by estimating its malondialdehyde (MDA) content (Beyotime Institute of Biotechnology, Haimen, China). MDA is an end product of the lipid peroxidation chain reaction and is frequently used as a marker of ROS production7. Glutathione peroxidase (GPx) activity was determined by hydrogen peroxide assay (Nanjing Jiancheng, Nanjing, China), and the disappearance rate of NADPH was recorded spectrophotometrically (412 nm) at 37 °C. GPx is an important cellular antioxidant that protects cells from the damaging effects of oxidation products, such as peroxidized lipids.


Fixed hearts were embedded in paraffin and sectioned at 5 μm. Antigen retrieval was performed in 10 mmol/L citrate buffer antigen, endogenous peroxidase activity was blocked by immersing the sections in 3% H2O2, and nonspecific epitope binding was blocked by incubation with 4% bovine serum albumin. The sections were then incubated with NOX4 polyclonal antibody (Santa Cruz Biotechnology, USA) and OPN polyclonal antibody (IBL, Japan) overnight at 4 °C, followed by an incubation for 30 min at room temperature with horse-radish peroxidase (HRP)-conjugated secondary antibody (1:200), and visualized with diaminobenzidine.

Western blot

Previously frozen heart tissues were lysed in RIPA buffer containing protease inhibitor (Beyotime, Haimen, China), minced with scissors, and sonicated for 10 s on ice. The homogenates were pelleted at 12 000×g for 15 min at 4 °C, and the supernatants were collected for Western blotting. Protein concentrations were determined using the Bradford protein assay (Beyotime, Haimen, China). Tissue lysates (30 μg) were separated on 10% Bis-Tris gels and electrotransferred onto polyvinylidene fluoride membranes, which were incubated overnight at 4 °C with antibodies specific to NOX4 (Santa Cruz Biotechnology, USA), OPN (IBL, Japan) and β-actin (Sigma-Aldrich, USA). After incubation with an HRP-conjugated secondary antibody, immune complexes were detected using the enhanced chemiluminescence method. Protein concentrations were quantified from the band intensities with ImageJ software (NIH, USA).

Cell culture

Cardiac fibroblasts were obtained from the ventricles of C57BL/6 mice and then grown in DMEM with 10% fetal bovine serum as previously described8, with minor modifications. Experiments were performed on secondary cultures. The cells were plated in MULTI-WELL 6-well plates, grown for 12 h in serum-free DMEM media, and then stimulated with Ang II (10−7 mol/L, Sigma-Aldrich, USA) for 4 h in the presence or absence of eplerenone (10−5 mol/L, Sigma-Aldrich, USA) and/or apocynin (10−5 mol/L, Sigma-Aldrich, USA) for 30 min. The relative NOX4 and OPN levels were determined by Western blotting.

Statistical analysis

The data are presented as the mean±SEM, unless otherwise indicated. Intergroup data were compared using a one-way analysis of variance (ANOVA) with the Tukey correction or unpaired -tests for continuous variables. Two-tailed P<0.05 was considered statistically significant.

Blood pressure and heart rate

The measurements of blood pressure and heart rate under drug treatment are summarized in Table 1. Elevated blood pressure induced by Ang II was significantly reduced by apocynin and/or eplerenone. The antihypertensive effect of apocynin was comparable to that of eplerenone, and combination treatment with both drugs failed to further decrease blood pressure. There were no significant differences in heart rate across the five treatment groups.

Cardiac hypertrophy

The Ang II-induced increase in HW/BW (the ratio of heart weight to body weight) was partially inhibited, albeit not significantly, by both apocynin and eplerenone (Table 1). The Ang II-induced increase in LVW/BW (the ratio of left ventricular weight to body weight) was significantly inhibited by apocynin and eplerenone. Cardiomyocyte breadth was measured to confirm the attenuation of ventricular hypertrophy by both apocynin and eplerenone (Figure 1).

Cardiac fibrosis

Representative photomicrographs of the heart and vessels are shown in Figures 2 and 3, respectively. Interstitial fibrosis was significantly increased after Ang II treatment in mice. Importantly, both apocynin and eplerenone almost completely abolished the Ang II-induced interstitial fibrosis. The percentage of perivascular fibrotic areas also increased markedly in Ang II-treated mice (47.1%±3.1%) compared with sham mice (13.2%±0.2%) (P<0.05). Compared with Ang II alone, treatment with apocynin, eplerenone or their combination significantly reduced the fibrotic area by 32.4%±1.8%, 29.8%±1.4%, and 29.0%±0.8%, respectively.

To further verify the reduction in fibrosis response by apocynin and/or eplerenone treatment, the protein expression of OPN and the NADPH oxidase subunit in the left ventricle was evaluated by immunohistochemistry. Positively labeled cells were rare in sham mice but abundant in Ang II-infused mice. Both apocynin and eplerenone remarkably blunted the level of Ang II-induced OPN and NOX4 staining (Figure 4).

Cardiac function and remodeling

Left ventricular hypertrophy, as judged by posterior wall thickness, was clearly induced by Ang II treatment (Table 2) and clearly inhibited by apocynin and/or eplerenone. Left ventricular systolic function was measured by percent fractional shortening (%FS) and was similar in all groups. Moreover, the E wave velocity (E/A) ratio was reduced, and isovolumic relaxation time (IVRT) was prolonged in the Ang II group, reflecting the impairment of left ventricular diastolic function. Finally, the left ventricular diastolic dysfunction caused by the administration of Ang II was improved by treatment with apocynin, eplerenone or their combination.

Myocardial oxidative stress

Ang II treatment triggered an increase in MDA levels (Figure 5A) but no change in the GPx activity in the left ventricle (Figure 5B). Treatment with apocynin and/or eplerenone inhibited an increase in the MDA levels in the hearts, but there was no change in GPx activity. The MDA levels and GPx activity observed in cardiac fibroblasts were consistent with those in cardiac tissue (Figure 5C and 5D).

Effects of Ang II, apocynin, and eplerenone on OPN and NOX4 expression

To investigate whether Ang II treatment stimulated the signaling cascade leading to cardiac fibrosis, we investigated NADPH oxidase and OPN protein levels in cardiac fibroblasts (Figure 6). At baseline, the NOX4 protein was abundantly expressed, whereas NOX1 and NOX2 (gp91phox) were expressed at very low levels (data not shown). Following Ang II treatment (10−7 mol/L), NOX4 and OPN protein levels were significantly upregulated. However, NOX4 and OPN protein expression was significantly downregulated when the cells were treated with apocynin (10−5 mol/L) and/or eplerenone (10−5 mol/L).


The most noteworthy finding in this study was that apocynin has cardioprotective effects comparable to that of eplerenone, triggering the reversal of cardiac fibrosis, attenuating oxidative stress, and lowering blood pressure. These effects imply that a pathway involving NADPH oxidase and OPN may regulate the process of Ang II-induced DHF in mice.

The roles of Ang II in cardiac hypertrophy and remodeling, as well as in the progression of DHF, have been well-established. ROS are believed to be associated with maladaptive responses such as myocardial hypertrophy, apoptosis, and interstitial fibrosis. Experimental data suggest that apocynin acts predominantly as an antioxidant in endothelial cells and vascular smooth muscle cells. However, whether this effect of alleviating excessive oxidation also applies to cardiac oxidative stress in Ang II-induced hypertensive mice with DHF is not yet clear. With this in mind, we observed that the increase in levels of MDA was significantly attenuated by treatment with apocynin in Ang II-induced hypertensive mice with DHF, while myocardial GPx activity remained unaffected, consistent with the findings of Virdis et al9 and Tian et al10.

More importantly, we also noted that treatment with eplerenone could suppress the formation of ROS. Eplerenone was reported to be superior to apocynin in aldosterone-induced hypertensive rats because eplerenone tends to reduce kidney damage and inhibit NOX expression11. Several clinical trials have indicated a remarkable protective impact of eplerenone on cardiac remodeling and heart failure12,13. These observations therefore suggest that lowered blood pressure may suppress ROS formation by modulating the transduction of shear stress-dependent signaling cascades in vascular cells and decrease ROS production accordingly. Further, in light of our observation that eplerenone did not enhance the apocynin-mediated improvement in blood pressure, or vice versa, we speculate that the effect of eplerenone on blood pressure that is associated with attenuated cardiac fibrosis and oxidative stress in Ang II-induced hypertensive mice is maximized, and additional treatment with apocynin has no effect.

NADPH oxidase is a transmembrane enzyme that produces superoxide (O2) by transferring an electron from NADPH to molecular oxygen. A growing body of data suggests that NADPH oxidase is involved in various experimental models of cardiovascular disease and exhibits high activity in human heart failure14,15,16,17; however, its molecular mechanism remains elusive. As an NADPH oxidase inhibitor, apocynin can prevent and reverse adrenocorticotropic hormone-induced hypertension in rats16. In addition, apocynin was also observed to lower SBP, and it was as effective as nifedipine in spontaneously hypertensive rats15. However, in Dahl salt-sensitive hypertensive rats with established heart failure, treatment with apocynin failed to reverse left ventricular inflammation and fibrosis17. In contrast, in our study, cardiac fibrosis in Ang II-induced hypertensive mice with DHF was significantly ameliorated by apocynin, which lowered the levels of both NADPH oxidase and OPN proteins. One possible reason for this inconsistency is the alleviation of excessive oxidation, as discussed above. Another possibility might be the reduced expression of OPN, which interacts with various extracellular matrices and is involved in the process of Ang II-induced fibrosis and heart failure5. Eplerenone treatment stimulated changes similar to those caused by apocynin, suggesting that eplerenone may affect the activation and function of NADPH oxidase and OPN.

Our findings also revealed a role for the NADPH oxidase inhibitor apocynin in further blocking the upregulation of OPN expression in Ang II-induced cardiac fibroblasts. If this observation holds true, we may speculate that the reversal of cardiac remodeling by apocynin might be attributed, at least in part, to the inhibition of NADPH oxidase secondary to the attenuation of OPN expression (known as NADPH oxidase-OPN signaling cascade). However, the possible existence of an OPN-NADPH oxidase signaling cascade cannot be ruled out because both NADPH oxidase and OPN levels can also be lowered by the aldosterone receptor blocker eplerenone.

A literature search did not uncover any evidence supporting either hypothesis. For example, Xie et al found that DPI (an inhibitor of the flavoprotein component of NADPH oxidase) inhibited Ang II-stimulated OPN expression in the ventricular myocytes and cardiac microvascular endothelial cells of adult rats, suggesting that NADPH oxidase may be a link between Ang II-stimulated ROS production and OPN expression18. Moreover, Umekawa et al observed that the CaOx monohydrate-induced production of OPN was significantly reduced after treatment with DPI19. In contrast, Lai et al proposed that an OPN-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase-9 activation in aortic mesenchymal cells20. Given these contradictory claims, it remains possible that NADPH oxidase and OPN might mutually promote each other's expression during the reversal of cardiac remodeling.

In summary, our findings provide evidence that apocynin had cardioprotective effects comparable to those of eplerenone in restoring DHF by triggering the reversal of cardiac fibrosis, attenuating oxidative stress, and lowering blood pressure, which collectively implicated a potential pathway involving NADPH oxidase and OPN in regulating Ang II-induced DHF in mice. Although further studies to elucidate these complex, multistep molecular pathways are warranted, the reduction of OPN in hypertensive heart might be a key step in perivascular fibrosis, and thus a prime target for clinical therapy.

Author contribution

Nan JIA and Wen-quan NIU designed the research; Yu-qiong LI and Xiao-bo LI performed the research; Shu-jie GUO, Shao-li CHU, Ping-jin GAO, and Ding-liang ZHU contributed new analytical tools and reagents; Yu-qiong LI and Wen-quan NIU analyzed the data; and Yu-qiong LI, Nan JIA, and Wen-quan NIU wrote and revised the paper.


Ang II, angiotensin II; OPN, osteopontin; NADPH, nicotinamide adenine dinucleotide phosphate; DHF, diastolic heart failure; ROS, reactive oxygen species; LVDd, left ventricular end-diastolic diameter; LVSd, left ventricular end-systolic diameter; PW, posterior wall thickness; IVRT, isovolumic relaxation time; MDA, malondialdehyde; GPx, glutathione peroxidase; Ab, antibody; ANOVA, one-way analysis of variance; LVW/BW, the ratio of the left ventricular weight to body weight.

This work was supported by the Natural Science Foundation of Shanghai (11ZR1430500), the Science Fund of Shanghai Jiao Tong University School of Medicine (11XJ21034), the Shanghai Rising Star Program (11QA1405500), and the National Natural Science Foundation of China (30900808).

Zile MR,Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part ICirculationYear: 200210513879311901053
Matsui Y,Jia N,Okamoto H,Kon S,Onozuka H,Akino M,et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophyHypertensionYear: 200443119520115123578
Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failureJ Clin InvestYear: 2005115500815765131
Weseler AR,Bast A. Oxidative stress and vascular function: implications for pharmacologic treatmentsCurr Hypertens RepYear: 2010121546120424954
Singh K,Sirokman G,Communal C,Robinson KG,Conrad CH,Brooks WW,et al. Myocardial osteopontin expression coincides with the development of heart failureHypertensionYear: 1999336637010024324
Jia N,Dong P,Ye Y,Qian C,Dai Q. Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunctionCardiovasc TherYear: 2012301172320973927
Ceconi C,Cargnoni A,Pasini E,Condorelli E,Curello S,Ferrari R. Evaluation of phospholipid peroxidation as malondialdehyde during myocardial ischemia and reperfusion injuryAm J PhysiolYear: 1991260H1057612012211
Nishioka T,Suzuki M,Onishi K,Takakura N,Inada H,Yoshida T,et al. Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone–mediated inflammationJ Cardiovasc PharmacolYear: 200749261817513943
Virdis A,Neves MF,Amiri F,Touyz RM,Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused miceJ HypertensYear: 20042253515076159
Tian N,Moore RS,Phillips WE,Lin L,Braddy S,Pryor JS,et al. NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertensionAm J Physiol-Regul Integ Comp PhysiolYear: 2008295R185865
Bayorh MA,Rollins-Hairston A,Adiyiah J,Lyn D,Eatman D. Eplerenone suppresses aldosterone/salt-induced expression of NOX-4J Renin Angiotensin Aldosterone SystYear: 20111219520121292834
Pitt B,Williams G,Remme W,Martinez F,Lopez-Sendon J,Zannad F,et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarctionCardiovasc Drugs TherYear: 200115798711504167
Zannad F,McMurray JJ,Krum H,van Veldhuisen DJ,Swedberg K,Shi H,et al. Eplerenone in patients with systolic heart failure and mild symptomsNew Engl J MedYear: 2011364112121073363
Gao L,Wang W,Li YL,Schultz HD,Liu D,Cornish KG,et al. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidaseCirc ResYear: 2004959374415459075
Baumer AT,Kruger CA,Falkenberg J,Freyhaus HT,Rosen R,Fink K,et al. The NAD(P)H oxidase inhibitor apocynin improves endothelial NO/superoxide balance and lowers effectively blood pressure in spontaneously hypertensive rats: comparison to calcium channel blockadeClin Exp HypertensYear: 2007292879917653964
Zhang Y,Chan MM,Andrews MC,Mori TA,Croft KD,McKenzie KU,et al. Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone–induced hypertension in the ratAm J HypertensYear: 200518910616053986
Yamamoto E,Kataoka K,Yamashita T,Tokutomi Y,Dong YF,Matsuba S,et al. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive ratHypertensionYear: 2007506576217709654
Xie Z,Pimental DR,Lohan S,Vasertriger A,Pligavko C,Colucci WS,et al. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen speciesJ Cellular PhysiolYear: 2001188132811382929
Umekawa T,Tsuji H,Uemura H,Khan SR. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystalsBJU IntYear: 20091041152019220254
Lai CF,Seshadri V,Huang K,Shao JS,Cai J,Vattikuti R,et al. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cellsCirc ResYear: 20069814798916709900

Article Categories:
  • Original Article

Keywords: angiotensin, Ang II-induced hypertensive mice, diastolic heart failure, eplerenone, apocynin, osteopontin, NADPH oxidase, NOX4.

Previous Document:  Selective estrogen receptor modulator BC-1 activates antioxidant signaling pathway in vitro via form...
Next Document:  High HIF-1? expression genotypes in oral lichen planus.